Inhibrx Biosciences stock gets a Moderate Buy consensus at USD 197.50

Published on 10/04/2026 at 12:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inhibrx Biosciences stock was last at USD 96.99 on Nasdaq on October 2, 2026, after a 48.3 percent Phase 2 response rate. Six brokerages issued a Moderate Buy consensus.

INBX, US45720N1037, Illustration mit AI erstellt.

Inhibrx Biosciences (ISIN US45720N1037) was last at USD 96.99 on Nasdaq on October 2, 2026, down 0.96 percent from the prior close. MarketBeat reported on October 3, 2026, that six brokerages had a Moderate Buy consensus and an average 12-month price target of USD 197.50.

Trial data set a clear benchmark

Inhibrx Biosciences reported on September 8, 2026, that INBRX-106 plus pembrolizumab delivered a 48.3 percent confirmed objective response rate in the Phase 2 HexAgon study, versus 26.5 percent for pembrolizumab alone. The analysis used a data cutoff of August 19, 2026, and included 63 evaluable patients.

The interim median progression-free survival was 9.6 months for the combination and 4.9 months for pembrolizumab alone. Six-month progression-free survival reached 72.4 percent versus 42.8 percent, giving the clinical program a measurable efficacy advantage while the data remain interim.

Consensus targets a higher valuation

The USD 197.50 average target lies 103.63 percent above the USD 96.99 reference price. MarketBeat said the six-brokerage mix comprised one sell, two hold ratings, two buy ratings and one strong buy rating, showing that the consensus masks a wide range of views.

The latest reported quarter adds a financial counterweight. According to MarketBeat, Inhibrx reported second-quarter 2026 earnings per share of USD -2.34 on August 13, 2026, missing the USD -2.28 consensus estimate by USD 0.06.

Stock remains below its yearly high

INBX was last at USD 96.99 on Nasdaq on October 2, 2026, with a 52-week range of USD 28.16 to USD 155.29 and a market capitalization of USD 1.4 billion. The clinical results offer a defined catalyst, while the negative quarterly earnings figure keeps execution and funding central to the valuation debate.